Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
Tanabe Pharma Corporation
Age
20–71
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with asthma disease
Written informed consent
Patients who completed the 24-week evaluation of study APTA-2217-05
You may not be if
% FEV1.0 \< 60% at both 18 weeks and 24 weeks measurements during APTA-2217-05
Patients with poorly controlled asthma between informed consent day and study starting day: need for oral or intravenous steroid therapy, hospitalization or any emergency visit, PEF value worsened for 2 or more consecutive days
Serious diseases
Clareo Health | Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07).
